MedTrace Logo

Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer

NCT02941536 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-12-27

No results posted yet for this study

Summary

This study assesses the number of CTCs before and 4-5 weeks after focal stereotactic radiotherapy, in single or fractionated dose, and correlate with the local and distant brain progression-free survival in patients with metastatic breast cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

Circulating tumor cells evaluation

Sample collection of circulating tumor cells (CTC) before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose.

Sponsors & Collaborators

  • International Atomic Energy Agency

    collaborator OTHER_GOV

  • AC Camargo Cancer Center

    lead OTHER

Principal Investigators

  • Douglas G Castro, MD, MSc · AC Camargo Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-01
Primary Completion
2018-10-15
Completion
2018-10-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02941536 on ClinicalTrials.gov